Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells (original) (raw)

Nature Medicine volume 10, pages 1187–1189 (2004)Cite this article

Abstract

We studied the effects of Lyn ablation on the survival of drug-resistant chronic myelogenous leukemia (CML) blast crisis cells using siRNA. Lyn siRNA reduced Lyn protein in both normal hematopoietic cells and BCR-ABL1-expressing (BCR-ABL1(+)) blasts by 80–95%. Within 48 h, siRNA-treated BCR-ABL1(+) blasts underwent apoptosis, whereas normal cells remained viable. This increased dependence on Lyn signaling for BCR-ABL1(+) blast survival provides the basis for rational treatment of drug-resistant CML blast crisis, particularly when lymphoid in nature.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Nowell, P.C. & Hungerford, D.A. Science 132, 1497 (1960) (abstract).
    Google Scholar
  2. Goldman, J.M. & Melo, J.V. N. Engl. J. Med. 349, 1451–1464 (2003).
    Article CAS Google Scholar
  3. Calabretta, B. & Perrotti, D. Blood 103, 4010–4022 (2004).
    Article CAS Google Scholar
  4. Amarante-Mendes, G.P. et al. Blood 91, 1700–1705 (1998).
    CAS Google Scholar
  5. Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
    Article CAS Google Scholar
  6. Gorre, M.E. et al. Science 293, 876–880 (2001).
    Article CAS Google Scholar
  7. Donato, N.J. et al. Blood 101, 690–697 (2003).
    Article CAS Google Scholar
  8. Danhauser-Riedl, S. et al. Cancer Res. 56, 3589–3596 (1996).
    CAS Google Scholar
  9. Ptasznik, A. et al. J. Exp. Med. 196, 667–678 (2002).
    Article CAS Google Scholar
  10. Elbashir, S.M. et al. Nature 411, 494–500 (2001).
    Article CAS Google Scholar
  11. Opalinska, J.B. & Gewirtz, A.M. Nat. Rev. Drug Discov. 1, 503–514 (2002).
    Article CAS Google Scholar
  12. Hu, Y. et al. Nat. Genet. 36, 453–461 (2004).
    Article CAS Google Scholar
  13. Dorsett, Y. et al. Nat. Rev. Drug Discov. 3, 318–329 (2004).
    Article CAS Google Scholar
  14. Luger, S. et al. Blood 99, 1150–1158 (2002).
    Article CAS Google Scholar
  15. Tatton, L. et al. J. Biol. Chem. 287, 4847–4853 (2003).
    Article Google Scholar

Download references

Acknowledgements

We thank D. Linnekin for providing us with Lyn cDNA. These studies were supported by grants from the Doris Duke Charitable Foundation (DDCF) to A.M.G., 1R01CA101859-01 (A.M.G.) and RO1CA90833 (S.G.E.) from the US National Institutes of Health, a SCOR grant from the Leukemia and Lymphoma Society (A.M.G. and S.G.E.). A. M. Gewirtz is a Distinguished Clinical Scientist of the DDCF.

Author information

Author notes

  1. Andrzej Ptasznik, Yuji Nakata and Stephen G Emerson: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, 19104, Pennsylvania, USA
    Andrzej Ptasznik, Yuji Nakata, Anna Kalota & Alan M. Gewirtz

Authors

  1. Andrzej Ptasznik
    You can also search for this author inPubMed Google Scholar
  2. Yuji Nakata
    You can also search for this author inPubMed Google Scholar
  3. Anna Kalota
    You can also search for this author inPubMed Google Scholar
  4. Stephen G Emerson
    You can also search for this author inPubMed Google Scholar
  5. Alan M. Gewirtz
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toAndrzej Ptasznik or Alan M. Gewirtz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Ptasznik, A., Nakata, Y., Kalota, A. et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.Nat Med 10, 1187–1189 (2004). https://doi.org/10.1038/nm1127

Download citation

This article is cited by